Therefore, due to the high demand for the discovery of more potent therapeutic options for BC patients and the necessity to further improve targeted therapies, in this study, we sought to further explore the combination between erdafitinib and quisinostat in BC with FGFR3 aberrations and understand the underlying mechanisms. The gene discussed is FGFR3; the disease is breast cancer.